N/A N=84 Randomized Prevention

Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH

Subarachnoid Hemorrhage

Bottom Line

View on ClinicalTrials.gov: NCT01137110 ↗

Enrolled (actual)

Serious AEs

4.8%

Results posted

Jul 2019

Primary outcome: Primary: In-hospital Seizures — 3; 1 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Brief LEV (Other); Extended LEV (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Washington University School of Medicine
Primary completion: Jan 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY In-hospital Seizures	3; 1	—

Summary

Our primary objective is to compare two treatment options for prevention of seizures following a subarachnoid hemorrhage and determine if a short-course regimen of levetiracetam is as efficacious in the prevention of in-hospital seizures when compared to an extended course.

Eligibility Criteria

Inclusion Criteria

Age >18 years of age
Diagnosis of spontaneous SAH

Exclusion Criteria

SAH secondary to trauma or arteriovenous malformation
Early death (defined as death within 3 days of presentation)
Known allergy to levetiracetam
Know seizure history on chronic AEDs
Pregnancy
Current incarceration

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01137110). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.